Clinical Trial

A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2026-04-06; most recent amendment 2026-06-28.
Trial Details
NCT Number NCT07524348
Lead Sponsor Samsung Bioepis Co., Ltd.
Conditions Advanced Solid Tumors
Enrollment 149 participants
Start Date 2026-03-23
Primary Completion 2030-07 (estimated)
Study Completion 2030-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-28